Biocon is among the companies that gave a good performance in 2016 and the stock surged 80 percent this year. Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of the company, said the company has gained traction in many emerging markets with its biosimilars.
A massive fire broke out at Syngene facilty near Bengaluru last evening but in a relief no casualties were reported as the incident took place after office hours. But, the damage in terms of value will run in several crores, said company's MD, Kiran Mazumdar Shaw.
Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said huge opportunities exist for Biocon in the US biosimilars market.
The CMD of Biocon Ltd, which was rated among the world's top ten employers in the biotechnology industry by an international magazine recently, said she is confident that the demonetised currency would be replaced by the new notes reasonably soon.
In an interview with CNCB-TV18, Kiran Mazumdar Shaw, CMD of Biocon said that people worldwide are losing confidence in entrenched political systems and many feel marginalized and neglected from the economic developments that happen.
The Chairperson and MD of Biocon Ltd said restrictive e-regulations that try to protect conventional bricks and mortar jobs are an example of this.
Automation and digital technologies will drive jobs of the future even as they cannibalise conventional employment while creating a large number of new opportunities, says biotech entrepreneur Kiran Mazumdar-Shaw.
The company has moved up to No 9 in 'Science 2016 Top Employer' ranking from No 13 last year, Biocon said in a release.
Biotechnology major Biocon on Friday said its manufacturing facility in Malaysia will be commercialised in the second half of the current financial year.
Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.
"The Indian economy has a strong bandwidth to deal with any possible after effects of the current state of tensions with Pakistan," Assocham Secretary General D S Rawat said.
Speaking to CNBC-TV18 Kiran Mazumdar Shaw, CMD, Bicon, said that India still has a long way to go on the infrastructure front. â€œPublic health is a major worry; it is under invested.â€ Mohandas Pai also spoke to the channel.
In his interview to Network 18, Narendra Modi had said that he did not reveal the full economic rot before his first Budget as he thought that it would depress business and investor sentiment further
Chevalier l'Ordre National de la Legion d'Honneur, created in 1802 by Napoleon Bonaparte, is the highest civilian award of the French Republic for outstanding contribution in diverse fields bestowed on citizens of the world.
The European Medicines Agency (EMA) has accepted to review Mylan and Biocon‘s application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.
YES Bank MD and CEO says the new Reserve Bank Governor should go beyond focusing on consumer price index as the anchor of monetary policy and must also take into account wholesale price index.
The biosimilar product, which is developed and manufactured by Biocon, has already been launched by its partner Fujifilm Pharma Co in Japan earlier this month.
Biotechnology major Biocon is banking on four advanced programmes aimed at treating cancer, diabetes and psoriasis to emerge as a leading global player in the field of biosimilars, Biocon Chairperson Kiran Mazumdar-Shaw has said.
As Brexit roiled financial markets, top industry leaders today said India cannot be in a denial mode as the referendum has opened a "pandora's box of grave uncertainties" and Indian companies, especially in IT sector, will have to rework their strategies for the region
The government eased foreign direct investment in pharma sector and Kiran Mazumdar Shaw of Biocon says it is a step in the right direction.
The Forbes '100 Most Powerful Women' in the world list 2016, topped by German Chancellor Angela Merkel, includes PepsiCo Chief Indra Nooyi, Biocon Founder Kiran Mazumdar-Shaw and HT Media head Shobhana Bhartia.
Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of data from the HERITAGE study at ...
These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.
Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.
Getting approval to sell the biosimilar drug Glargine in Japan will open doors for the company, feels Kiran Mazumdar Shaw, Chairperson and Managing Director of Biocon.